|
[Related PubMed/MEDLINE] Total Number of Papers: 51
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
A Pilot Randomized Treatment-Controlled Trial Comparing Vitamin B6 with Broad-Spectrum Micronutrients for Premenstrual Syndrome. |
ES, PMDD, PMS |
2 |
2020 |
Biomarker validation of a new case definition of menstrual cycleassociated syndrome (MCAS) Opinion Paper. |
ACOG, MCAS |
3 |
2020 |
Does Adding Fluoxetine to Combined Oral Contraceptives Containing Drospirenone Improve the Management of Severe Premenstrual Syndrome? A 6-Month Randomized Double-Blind Placebo-Controlled Three-Arm Trial. |
COC, DSRP, PMS |
4 |
2020 |
Menstrual Cycle Characteristics and Premenstrual Syndrome Prevalence Based on the Daily Record of Severity of Problems in Korean Young Adult Women. |
PMS |
5 |
2020 |
Study on urinary metabolomics of premenstrual dysphoric disorder patients with liver-qi depression syndrome treated with Xiaoyaosan: Study Protocol Clinical Trial (SPIRIT Compliant). |
LC-MS, PMDD |
6 |
2020 |
The role of immune and oxidative pathways in menstrual cycle associated depressive, physio-somatic, breast and anxiety symptoms: Modulation by sex hormones. |
AOPP, AREase, Hp, hs-CRP, LOOH, MC, MCAS, MDA, NOx, PMS, PON, TRAP |
7 |
2020 |
The uterine-chemokine-brain axis: menstrual cycle-associated symptoms (MCAS) are in part mediated by CCL2, CCL5, CCL11, CXCL8 and CXCL10. |
MCAS |
8 |
2019 |
Lowered Plasma Steady-State Levels of Progesterone Combined With Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains. |
ACOG, PMS |
9 |
2019 |
Thalamocortical dysconnectivity in premenstrual syndrome. |
fMRI, HCs, PFC, PMS |
10 |
2019 |
The diagnosis of premenstrual mood disorders: Do we have it backwards? |
--- |
11 |
2019 |
The menstrual cycle may not be limited to the endometrium but also may impact gut permeability. |
LPS |
12 |
2018 |
A lecithin phosphatidylserine and phosphatidic acid complex (PAS) reduces symptoms of the premenstrual syndrome (PMS): Results of a randomized, placebo-controlled, double-blind clinical trial. |
CAR, CBG, MEMS, PA, PAS, PMDD, PMS, PS, PSST |
13 |
2018 |
Acupuncture and acupressure for premenstrual syndrome. |
CBM, CI, CNKI, ISPMD, MD, PMDD, PMS, RCT, RR, SSRIs |
14 |
2018 |
Hippocampal fractional amplitude of low-frequency fluctuation and functional connectivity changes in premenstrual syndrome. |
EPI, fALFF, FC, HIPP, MCC, mPFC, OFC, PC, PCC, PMS, PMS |
15 |
2018 |
Larger volume and different functional connectivity of the amygdala in women with premenstrual syndrome. |
ACC, FC, HC, mPFC, MRI, PMS |
16 |
2018 |
Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. |
COC |
17 |
2018 |
Premenstrual Syndrome Diagnosis: A Comparative Study between the Daily Record of Severity of Problems (DRSP) and the Premenstrual Symptoms Screening Tool (PSST). |
BMI, PABAK, PMDD, PMS, PRIME-MD, PSST |
18 |
2018 |
Remote intervention using smartphone for rural women suffering from premenstrual syndrome: A propensity score matched analysis. |
CBT, PMS |
19 |
2018 |
Semi-Individualized Homeopathy Add-On Versus Usual Care Only for Premenstrual Disorders: A Randomized, Controlled Feasibility Study. |
ITT, PP, UC |
20 |
2017 |
Abnormal Spontaneous Brain Activity in Women with Premenstrual Syndrome Revealed by Regional Homogeneity. |
ACC, IFC, ITC, MFC, PMS, ReHo, rs-fMRI |
21 |
2017 |
Altered fractional amplitude of low frequency fluctuation in premenstrual syndrome: A resting state fMRI study. |
ACC, fMRI, PMDD, PMS |
22 |
2017 |
Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. |
COC |
23 |
2017 |
Cortisol awakening response is blunted and pain perception is increased during menses in cyclic women. |
CAR, STAI-T, VAS |
24 |
2017 |
Predictors of premenstrual impairment among women undergoing prospective assessment for premenstrual dysphoric disorder: a cycle-level analysis. |
PMDD |
25 |
2017 |
Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS). |
C-PASS, PMDD |
26 |
2017 |
Treatment of Premenstrual Breakthrough of Depression With Adjunctive Oral Contraceptive Pills Compared With Placebo. |
DRSP/EE, MADRS, OCP, PME |
27 |
2017 |
Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. |
GAMSA, PMDD |
28 |
2016 |
Study Protocol for a Randomized Double Blind, Treatment Control Trial Comparing the Efficacy of a Micronutrient Formula to a Single Vitamin Supplement in the Treatment of Premenstrual Syndrome. |
PMDD, PMS |
29 |
2015 |
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial. |
CGI, IDS-C, PMDD, PMTS, SRIs, SSRI |
30 |
2014 |
Baduanjin exercise improved premenstrual syndrome symptoms in Macau women. |
PMS |
31 |
2014 |
[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 g in the treatment of premenstrual dysphoric disorder: a randomized, double blind placebo-controlled study]. |
CGI, PMDD |
32 |
2013 |
The role of anxiety sensitivity in the experience of menstrual-related symptoms reported via daily diary. |
AS, MDQ |
33 |
2012 |
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome. |
DSR, OC, PMDD, PMS |
34 |
2012 |
Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. |
PMDD |
35 |
2012 |
Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. |
PMDD, PMS |
36 |
2011 |
Comparing the Effects of Echinophora-platyloba, Fennel and Placebo on Pre-menstrual Syndrome. |
PMS |
37 |
2011 |
Ethinyl estradiol 20mug/drospirenone 3mg 24/4 oral contraceptive for the treatment of functional impairment in women with premenstrual dysphoric disorder. |
EE, PMDD |
38 |
2010 |
Explorative evaluation of the impact of premenstrual disorder on daily functioning and quality of life. |
HRQoL, PMDD, PMS |
39 |
2010 |
Explorative evaluation of the impact of severe premenstrual disorders on work absenteeism and productivity. |
PMDD, PMS, PSST, WPAI |
40 |
2009 |
Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial. |
PMDD |
41 |
2008 |
Frequency, intensity and impact of premenstrual syndrome in medical students. |
MCS, PCS, PMDD, PMS, SF36 |
42 |
2008 |
Levetiracetam for treatment of premenstrual dysphoric disorder: a pilot, open-label study. |
CGI, MINI, PMDD |
43 |
2007 |
Differences in symptom scores and health outcomes in premenstrual syndrome. |
PMDD, PMS, SF-36 |
44 |
2007 |
Premenstrual dysphoric disorder--a neglected diagnosis? Preliminary study on a sample of Croatian students. |
PMDD |
45 |
2007 |
Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. |
PMS |
46 |
2006 |
Daily Record of Severity of Problems (DRSP): reliability and validity. |
PMDD |
47 |
2005 |
Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase. |
PMDD |
48 |
2005 |
Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. |
PMDD |
49 |
2005 |
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. |
EE, OC, PMDD |
50 |
2002 |
Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. |
CGI, PGI, PLC, PMDD, PMTS-C |
51 |
2000 |
Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. |
CGI-I, HAM-D, PMDD, Q-LES-Q, SAS |
|